Skip to Content
NCI Formulary
Contact NExT
Show menu
Search this site
Last Updated: 04/22/22

Available Agents

Click on column header to sort by Agent Name, Company or Agent Class

Agent Name NSC Number Company Agent Class Agent Target/Molecular Target(s)
Abemaciclib 783671 Eli Lilly and Company CDK4/6 Inhibitor CDK4, CDK6
Adavosertib 751084 AstraZeneca WEE1 kinase inhibitor WEE1
Alectinib 794611 Genentech ALK inhibitor, tyrosine kinase inhibitor ALK, RET
Atezolizumab 783608 Genentech PD-L1 blocking monoclonal antibody PD-L1
Avelumab 799232 EMD Serono, Inc. PD-L1 Inhibitor PD-L1
Bevacizumab 704865 Genentech Anti-angiogenesis inhibitor, monoclonal antibody VEGF
Blinatumomab 765986 Amgen Inc Bispecific T-cell engager (BiTE) monoclonal antibody CD3, CD19
Capivasertib 782347 AstraZeneca serine/threonine kinase (AKT) inhibitor AKT 1, AKT 2, AKT 3
Cediranib 732208 AstraZeneca VEGF RTK inhibitor VEGFR-1, VEGFR-2, VEGFR-3, c-Kit
Ceralasertib 802785 AstraZeneca ATR kinase inhibitor ATR
Cobimetinib 781257 Genentech MEK1/2 inhibitor MEK1/2
Durvalumab 778709 AstraZeneca PD-L1 blocking monoclonal antibody PD-L1, CD80
Elzovantinib Turning Point Therapeutics Small (low molecular weight), macrocyclic tyrosine kinase inhibitor MET, SRC, CSF1R
Ensartinib 784729 Xcovery Holding Company LLC ALK inhibitor ALK, TrkA, TrkC, ROS, EphA2, c-MET
Ipilimumab 732442 Bristol-Myers Squibb anti-CTLA-4 monoclonal anibody CTLA-4
Larotrectinib 788607 Bayer Tyrosine kinase inhibitor NTRK-1, NTRK-2, NTRK-3 gene fusions; TrkA/B/C fusion proteins
Mirdametinib SpringWorks Therapeutics, Inc. MEK1/2 inhibitor MEK1, MEK2
Mogamulizumab 791064 Kyowa Hakko Kirin Co., Ltd. anti-CCR4 monoclonal antibody CC chemokine receptor 4 (CCR4)-expressing cells
Nivolumab 748726 Bristol-Myers Squibb PD-1 blocking monoclonal antibody PD-1
Obinutuzumab 793436 Genentech anti-CD20 monoclonal antibody CD20
Olaparib 747856 AstraZeneca PARP inhibitor PARP-1, PARP-2, PARP-3
Pertuzumab 740102 Genentech anti-HER2 monoclonal antibody HER2/neu
Regorafenib 821745 Bayer L01XE21 VEGFR1, VEGFR2, VEGFR3, TIE2, PDGFRB, FGFR1, KIT, RET, RAF1, BRAF
Repotrectinib Turning Point Therapeutics Small (low molecular weight), macrocyclic tyrosine kinase inhibitor ROS1, TRK, ALK, JAK, FAK, SRC
Savolitinib 785348 AstraZeneca MET kinase inhibitor MET
Selpercatinib 812076 Eli Lilly and Compnay Selective RET Inhibitor RET
SX-682   Syntrix Biosystems, Inc. CXCR1 and CXCR2 inhibitor CXCR1 and CXCR2 expressing cells
Talimogene laherparepvec 785349 Amgen Inc Genetically modified oncolytic virus  
Trastuzumab 688097 Genentech anti-HER2 monoclonal antibody HER2/neu
Tremelimumab 744483 AstraZeneca anti-CTLA-4 monoclonal anibody CTLA-4
Vemurafenib 761431 Genentech BRAF mutant v600 inhibitor BRAF V600 mutant, CRAF, ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5, FGR